89 related articles for article (PubMed ID: 26480800)
1. [Semaphorin 4 in multiple sclerosis].
Nakatsuji Y; Okuno T; Koda T; Mochizuki H
Nihon Rinsho; 2015 Sep; 73 Suppl 7():821-5. PubMed ID: 26480800
[No Abstract] [Full Text] [Related]
2. Semaphorins 3A and 7A: potential immune and neuroregenerative targets in multiple sclerosis.
Eixarch H; Gutiérrez-Franco A; Montalban X; Espejo C
Trends Mol Med; 2013 Mar; 19(3):157-64. PubMed ID: 23419749
[TBL] [Abstract][Full Text] [Related]
3. New pieces in the puzzle: how does interferon-beta really work in multiple sclerosis?
Mitsdoerffer M; Kuchroo V
Ann Neurol; 2009 May; 65(5):487-8. PubMed ID: 19479722
[No Abstract] [Full Text] [Related]
4. The role of immune semaphorins in multiple sclerosis.
Okuno T; Nakatsuji Y; Kumanogoh A
FEBS Lett; 2011 Dec; 585(23):3829-35. PubMed ID: 21420960
[TBL] [Abstract][Full Text] [Related]
5. [Regulation of immune responses by immune semaphorins].
Ito D; Nojima S; Kumanogoh A
Nihon Rinsho; 2012 Sep; 70(9):1633-43. PubMed ID: 23012815
[TBL] [Abstract][Full Text] [Related]
6. Viral semaphorin inhibits dendritic cell phagocytosis and migration but is not essential for gammaherpesvirus-induced lymphoproliferation in malignant catarrhal fever.
Myster F; Palmeira L; Sorel O; Bouillenne F; DePauw E; Schwartz-Cornil I; Vanderplasschen A; Dewals BG
J Virol; 2015 Apr; 89(7):3630-47. PubMed ID: 25589653
[TBL] [Abstract][Full Text] [Related]
7. The role of immune semaphorins in the pathogenesis of multiple sclerosis: Potential therapeutic targets.
Lotfi R; Nasiri Kalmarzi R; Rajabinejad M; Hasani S; Zamani F
Int Immunopharmacol; 2021 Jun; 95():107556. PubMed ID: 33756227
[TBL] [Abstract][Full Text] [Related]
8. Bench to bedside: tempering antigen-presenting cells in multiple sclerosis.
Prod'homme T; Zamvil SS
Nat Med; 2008 Jun; 14(6):614-5. PubMed ID: 18535577
[No Abstract] [Full Text] [Related]
9. Immunological study of IFNbeta-1a-treated and untreated multiple sclerosis patients: clarifying IFNbeta mechanisms and establishing specific dendritic cell immunotherapy.
Berghella AM; Totaro R; Pellegrini P; Contasta I; Russo T; Carolei A; Adorno D
Neuroimmunomodulation; 2005; 12(1):29-44. PubMed ID: 15756051
[TBL] [Abstract][Full Text] [Related]
10. Semaforin Sema4D in the immune system in multiple sclerosis.
Kuklina EM; Baidina TV; Danchenko IY; Nekrasova IV
Bull Exp Biol Med; 2014 Jun; 157(2):234-7. PubMed ID: 24952493
[TBL] [Abstract][Full Text] [Related]
11. Suppressor-inducer T-cells in multiple sclerosis.
Rose LM; Ledbetter JA; Ginsberg AH; Clark EA; Rothstein TL
N Engl J Med; 1987 Jul; 317(2):118-9. PubMed ID: 2953974
[No Abstract] [Full Text] [Related]
12. IFN-beta inhibits human Th17 cell differentiation.
Ramgolam VS; Sha Y; Jin J; Zhang X; Markovic-Plese S
J Immunol; 2009 Oct; 183(8):5418-27. PubMed ID: 19783688
[TBL] [Abstract][Full Text] [Related]
13. [Immune semaphorins: involvement of semaphorins in various phases of immune responses].
Takegahara N; Kumanogoh A
Tanpakushitsu Kakusan Koso; 2009 Jun; 54(8 Suppl):1101-7. PubMed ID: 21089548
[No Abstract] [Full Text] [Related]
14. Decrease of suppressor inducer (CD4+2H4+) T cells in multiple sclerosis cerebrospinal fluid.
Chofflon M; Weiner HL; Morimoto C; Hafler DA
Ann Neurol; 1989 May; 25(5):494-9. PubMed ID: 2528316
[TBL] [Abstract][Full Text] [Related]
15. Elevation of Sema4A implicates Th cell skewing and the efficacy of IFN-β therapy in multiple sclerosis.
Nakatsuji Y; Okuno T; Moriya M; Sugimoto T; Kinoshita M; Takamatsu H; Nojima S; Kimura T; Kang S; Ito D; Nakagawa Y; Toyofuku T; Takata K; Nakano M; Kubo M; Suzuki S; Matsui-Hasumi A; Uto-Konomi A; Ogata A; Mochizuki H; Sakoda S; Kumanogoh A
J Immunol; 2012 May; 188(10):4858-65. PubMed ID: 22491253
[TBL] [Abstract][Full Text] [Related]
16. Immune semaphorins: a new area of semaphorin research.
Kumanogoh A; Kikutani H
J Cell Sci; 2003 Sep; 116(Pt 17):3463-70. PubMed ID: 12893810
[TBL] [Abstract][Full Text] [Related]
17. [Behavior of T lymphocytes, T helper and T suppressor, in multiple sclerosis. Preliminary report].
Tilbery CP; Lima JG; Scheinberg MA; Santos LM; Yamada FT
Rev Paul Med; 1984; 102(4):181-3. PubMed ID: 6240108
[No Abstract] [Full Text] [Related]
18. Molecular oracles for multiple sclerosis therapy.
Wekerle H; Hohlfeld R
Nat Med; 2010 Apr; 16(4):376-7. PubMed ID: 20376043
[No Abstract] [Full Text] [Related]
19. Diverse roles for semaphorin-plexin signaling in the immune system.
Takamatsu H; Kumanogoh A
Trends Immunol; 2012 Mar; 33(3):127-35. PubMed ID: 22325954
[TBL] [Abstract][Full Text] [Related]
20. Targeting semaphorins in MS as a treatment strategy to promote remyelination: A tale of mice, rats and men.
Kremer D; Hartung HP; Küry P
Mult Scler; 2015 Nov; 21(13):1616-7. PubMed ID: 26432852
[No Abstract] [Full Text] [Related]
[Next] [New Search]
